Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Investors who purchased America's Car-Mart, Inc. securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Performance and Market Reaction - On September 4, 2025, America's Car-Mart, Inc. reported a first-quarter loss of 69 cents per share, compared to a net loss of 15 cents per share in the same period the previous year [3]. - Following the release of these results, America's Car-Mart, Inc. stock experienced a significant decline of 18.2% on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Points - Rosen Law Firm is reminding investors of Sina Corporation about the November 18, 2025 deadline to join a securities class action related to the merger that occurred between October 13, 2020, and March 22, 2021 [1][2] Group 1: Class Action Details - Investors who sold ordinary shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by November 18, 2025 [3] - The lawsuit alleges that defendants created a fraudulent scheme to depress the value of Sina's shares to avoid paying a fair price during the merger [5] Group 2: Allegations Against Defendants - The defendants are accused of misrepresenting and omitting material information in Sina's proxy materials, which were necessary for shareholders to make informed decisions regarding the merger [5] - Specific allegations include the concealment of the true value of Sina's investment in TuSimple and that the merger offer of $43.30 per share significantly undervalued Sina's ordinary shares [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for misrepresentations regarding the market demand and launch of its sleep apnea device, Inspire V, during the specified Class Period from August 6, 2024, to August 4, 2025 [2][6]. Group 1: Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements about the demand for Inspire V and the necessary steps taken for its launch, leading to investor damages when the truth was revealed [6]. - Investors who purchased common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm for more information [4][7]. - A lead plaintiff must be appointed by January 5, 2026, to represent other class members in the litigation [2][4]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [5]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

Core Viewpoint - Rosen Law Firm is urging investors of Cytokinetics, Inc. to take action before the November 17, 2025 deadline related to a securities class action lawsuit concerning misleading statements about the company's New Drug Application for aficamten [2][6]. Group 1: Class Action Details - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - The lawsuit alleges that Cytokinetics made false statements regarding the timeline for the NDA submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who acquired Synopsys securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 30, 2025, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Synopsys made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the Class Period [5]. - Specific claims include the negative impact of Synopsys' focus on artificial intelligence customers on its Design IP business and the misleading nature of positive statements made by the company regarding its prospects [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Quanex Building Products Corporation to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from December 12, 2024, to September 5, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Quanex securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by November 18, 2025 [3]. - The lawsuit alleges that Quanex made false and misleading statements regarding its tooling and equipment maintenance, which were significantly underinvested, leading to degraded conditions and potential significant costs [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including the largest settlement against a Chinese company and recovering hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm is urging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to stock purchases made between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients, including malfunctions that could result in underinfusion, overinfusion, or non-delivery of fluids [6]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5].

Core Points - Rosen Law Firm is reminding investors of aTyr Pharma, Inc. to secure counsel before the December 8, 2025 lead plaintiff deadline for a securities class action [2][4] - Investors who purchased aTyr Pharma common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6] - The lawsuit alleges that aTyr Pharma made misleading statements regarding the efficacy of its drug Efzofitimod, which led to investor damages when the truth was revealed [6] Company Information - aTyr Pharma, Inc. is currently facing a class action lawsuit due to allegations of providing false and misleading information about its drug's capabilities [6] - The Rosen Law Firm has a strong track record in securities class actions, having recovered hundreds of millions of dollars for investors and being recognized for its success in this field [5] Legal Process - Investors interested in joining the class action can do so by contacting the Rosen Law Firm through their website or phone [4][7] - It is important to note that no class has been certified yet, and investors are not represented by counsel unless they retain one [8]

Core Viewpoint - Rosen Law Firm is urging investors of Quanex Building Products Corporation to take action before the November 18, 2025 deadline related to a securities class action lawsuit [2][4] Group 1: Class Action Details - The class action pertains to investors who purchased Quanex securities between December 12, 2024, and September 5, 2025 [2] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3] - A lead plaintiff must be appointed by November 18, 2025, to represent other class members in the litigation [4] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [5] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company [5] - Rosen Law Firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions for investors [5] Group 3: Case Allegations - The lawsuit alleges that Quanex made false and misleading statements regarding its tooling and equipment maintenance policies, which were underinvested [6] - It is claimed that the conditions of the tooling and equipment had degraded to near catastrophic levels, leading to significant costs and delays in expected benefits from the Tyman integration [6] - The lawsuit asserts that the positive statements made by Quanex about its business operations were materially misleading [6]

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 15, 2025, to represent other class members [4][6]. Group 2: Legal Representation - Investors are advised to choose qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements achieved [5]. Group 3: Allegations Against MoonLake - The complaint alleges that during the class period, MoonLake made false or misleading statements regarding its product SLK, particularly in comparison to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [6].